Recent studies have focused on the intersection of GLP-1|GIP|glucagon receptor activator therapies and dopaminergic signaling. While GLP agonists are widely employed for managing type 2 diabetes, their potential impacts on reinforcement circuits, specifically influenced by dopamine pathways, are gaining considerable focus. This paper details a b… Read More